@prefix nt: .
@prefix this: .
@prefix sub: .
@prefix drugbank: .
@prefix np: .
@prefix mondo: .
@prefix pav: .
@prefix infores: .
@prefix xsd: .
@prefix orcid: .
@prefix rdfs: .
@prefix pmid: .
@prefix ncit: .
@prefix rdf: .
@prefix biolink: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo .
}
sub:assertion {
drugbank:DB00391 a biolink:Drug;
rdfs:label "Sulpiride";
biolink:category biolink:Drug .
mondo:0005618 a biolink:Disease;
rdfs:label "Anxiety disorder";
biolink:category biolink:Disease .
sub:association a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
rdf:object mondo:0005618;
rdf:predicate biolink:treats;
rdf:subject drugbank:DB00391;
rdfs:label "First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics.";
biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
biolink:has_population_context sub:context;
biolink:publications pmid:31077503;
biolink:relation ncit:C94303 .
sub:context a biolink:Cohort;
rdfs:label "Adults";
biolink:category biolink:Cohort .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
npx:hasSignature "ZdOucn3Hz/j09uwy7a6lWABxotTAXQ9U2VcgxOyreBlPk204T7wV5QTeeMvHlFsBgA4Bq5tS+cYnCgGbMU/+VkSSQM5Iv87owSFJud35c2YUZMcWYUNl/1Fink4hEXelfDvDyz3xHonIbhcwflWZ5FVbIhPSOuzb6SYyQ5FErMs=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2022-09-16T11:50:59.318292"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-1501-1082;
nt:wasCreatedFromTemplate .
biolink: pav:version "2.3.0" .
}